University of California San Francisco

Response To: Feasibility of a Tumor Progression Model in PRKAR1A-inactivated Melanomas.

Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH PMID: 33859070

Response To: Feasibility of a Tumor Progression Model in PRKAR1A-inactivated Melanomas.

Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH PMID: 33859070

Response To: Feasibility of a Tumor Progression Model in PRKAR1A-inactivated Melanomas.

Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH PMID: 33859070

Response To: Feasibility of a Tumor Progression Model in PRKAR1A-inactivated Melanomas.

Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH PMID: 33859070

Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council

Lawrence F.Eichenfield MD, Ayan Kusari, Allison M.Han, SébastienBarbarot MD, PhD, Mette Deleuran MD, DMSce PeterLio MD, Danielle Marcoux MD, AudreyNosbaum MD, PhD, Jean-FrancoisStalder MD PMID:

Cutaneous Leishmaniasis Caused by an Unknown Leishmania Strain, Arizona, USA.

de Almeida M, Zheng Y, Nascimento FS, Bishop H, Cama VA, Batra D, Unoarumhi Y, Afghan AK, Shi VY, LeBoit PE, Liu EW, Donovan FM PMID: 34013870

Molecular Genetics of Sebaceous Neoplasia.

North JP PMID: 34023105

Equity and the JAMA Network.

Fontanarosa PB, Flanagin A, Ayanian JZ, Bonow RO, Bressler NM, Christakis D, Disis ML, Josephson SA, Kibbe MR, Öngür D, Piccirillo JF, Redberg RF, Rivara FP, Shinkai K, Yancy CW PMID: 34081110

Detection of cryptogenic malignancies from metagenomic whole genome sequencing of body fluids.

Gu W, Talevich E, Hsu E, Qi Z, Urisman A, Federman S, Gopez A, Arevalo S, Gottschall M, Liao L, Tung J, Chen L, Lim H, Ho C, Kasowski M, Oak J, Holmes BJ, Yeh I, Yu J, Wang L, Miller S, DeRisi JL, Prakash S, Simko J, Chiu CY PMID: 34074327

Melanoma pathology: new approaches and classification.

Yeh I, Bastian BC PMID: 34060071